Donepezil Hydrochloride
Product Images NDC 68151-3114

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 68151-3114). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Carilion Materials Management, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Str (94fb4253 7822 4043 8ef9 0f8d93642feb 01)

Chemical structure of donepezil hydrochloride showing its molecular arrangement including methoxy groups, a piperidine ring, and a benzyl group with a hydrochloride component.*

FDA Label Image

Fig.1 (94fb4253 7822 4043 8ef9 0f8d93642feb 02)

A line graph showing ADAS-cog change from baseline with mean and standard error over 30 weeks of drug treatment. The x-axis represents weeks of treatment, while the y-axis represents cognitive change with clinical improvement at the top and clinical decline at the bottom. The graph compares Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day dosages versus placebo, indicating differences in cognitive change over time during and after treatment.*

FDA Label Image

Figure 2 (94fb4253 7822 4043 8ef9 0f8d93642feb 03)

A cumulative percentage of patients graph showing changes from baseline in ADAS-cog scores. It compares three groups: Donepezil Hydrochloride Tablets 10 mg/day, 5 mg/day, and placebo, with points indicating 7 and 4 score improvements and no change. An inset table summarizes the percentage of patients achieving score changes of -7, -4, and 0 for each treatment group.*

FDA Label Image

Figure 3 (94fb4253 7822 4043 8ef9 0f8d93642feb 04)

A bar chart comparing the percentage of patients by CIBIC-plus rating categories for Donepezil Hydrochloride 10 mg/day, 5 mg/day, and placebo groups. The categories range from markedly improved to markedly worse, showing patient distribution for each treatment group along the x-axis.*

FDA Label Image

5 (94fb4253 7822 4043 8ef9 0f8d93642feb 05)

A line graph showing the mean change from baseline in ADAS-cog scores over 15 weeks of drug treatment with Donepezil Hydrochloride Tablets at 10 mg/day and 5 mg/day doses, compared to placebo. The y-axis indicates cognitive change (clinical improvement or decline), and the x-axis represents weeks of treatment. Both Donepezil groups show clinical improvement, while placebo remains near baseline.*

FDA Label Image

Figure 5 (94fb4253 7822 4043 8ef9 0f8d93642feb 06)

A cumulative percentage of patients graph comparing Donepezil Hydrochloride Tablets 5 mg/day and 10 mg/day to placebo, showing change from baseline on the x-axis and cumulative patient percentage on the y-axis. The chart includes reference lines at 7 points, 4 points, and no change, with a table summarizing the percentage of patients achieving specific changes in ADAS-cog scores for each treatment group.*

FDA Label Image

Figure 6 (94fb4253 7822 4043 8ef9 0f8d93642feb 07)

Bar chart showing the distribution of CIBIC-plus ratings for patients receiving Donepezil Hydrochloride tablets at 10 mg/day, 5 mg/day, and placebo. The x-axis lists categories from markedly improved to markedly worse, while the y-axis represents the percentage of patients in each category. The chart compares patient improvement or decline across three groups.*

FDA Label Image

Figure 7 (94fb4253 7822 4043 8ef9 0f8d93642feb 08)

A line graph showing the change from baseline in SIB (Severe Impairment Battery) mean score over 6 months of drug treatment. Two groups are compared: Donepezil Hydrochloride Tablets 10 mg/day and placebo. The Donepezil group shows clinical improvement over time, while the placebo group shows a decline. Error bars indicate standard error.*

FDA Label Image

Figure 8 (94fb4253 7822 4043 8ef9 0f8d93642feb 09)

A cumulative frequency curve comparing the percentage of patients versus SIB (Severe Impairment Battery) change from baseline for Donepezil Hydrochloride Tablets 10 mg/day and placebo groups. The graph depicts the distribution of patient responses, with Donepezil showing a shift towards greater SIB improvement compared to placebo.*

FDA Label Image

Figure 9 (94fb4253 7822 4043 8ef9 0f8d93642feb 10)

Line graph showing the time course of change from baseline in ADCS-ADL-Severe scores over 6 months of treatment comparing Donepezil Hydrochloride Tablets 10 mg/day and placebo. The y-axis represents the mean change from baseline, with clinical improvement above and clinical decline below baseline. Data points with error bars depict scores at 0, 3, and 6 months.*

FDA Label Image

Figure 10 (94fb4253 7822 4043 8ef9 0f8d93642feb 11)

A cumulative percentage plot comparing patients treated with Donepezil Hydrochloride 10 mg/day tablets to those given a placebo. The x-axis shows ADCS-ADL change from baseline, with negative values to the right indicating improvement. The y-axis shows cumulative percentage of patients. The Donepezil group data points are marked with black circles, and placebo group points with white squares, illustrating differences in functional change over baseline.*

FDA Label Image

Logo (94fb4253 7822 4043 8ef9 0f8d93642feb 12)

FDA Label Image

Logo (94fb4253 7822 4043 8ef9 0f8d93642feb 13)

FDA Label Image

Label Image (Lbl681513114)

Donepezil Hydrochloride 10 mg tablet label displays the product name and strength along with manufacturing details including manufacturer Torrent, lot number BN753030, expiration date 07/14, and a barcode with the number 0000003114. Label specifies 'Rx only' and includes product designation PDM:3114.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.